A perspective study on hyperlactic acidemia treated with alafenamide tenofovir after entecavar treatment in chronic hepatitis B patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035861

Enrollment

Unknown

Registered

2020-08-18

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlactic acidemia

Interventions

enticavir+sodium hydrogen carbonate:enticavir+sodium hydrogen carbonate

alafenamide tenofovir:alafenamide tenofovir

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-65 years; 2. HBsAg and/or HBVDNA positive exceed 6 months; 3. a history of treatment with entecavir and lacitic >2.2; 4. signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. HCC or AFP>100ng/ml; 2. pregrant or breasting women; 3. co-infection HAV HCV,HDV,HEV,HIV and with other chronic hepatitis; 4. Poor compliance.

Design outcomes

Primary

Measure	Time frame
lacitic normality rate;	—

Secondary

Measure	Time frame
lacitic;lacitic acid toxic rate;renal dysfunction rate;electrolyte disturbance rate;	—

Countries

China

Contacts

Public ContactQi Xun

Shanghai Public Health Clinical Center

qixun@shphc.org.cn+86 18916121139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026